Regulatory FDA delays verdict on Beren’s rare disease drug by three months BioSpaceBeren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17.Rare DiseaseRead full story pharminent May 29, 2026 (Last updated: May 30, 2026) BioSpace Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17. Rare Disease Read full story Post navigation Previous: Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s InnoventNext: Replimune gives cancer immunotherapy a third try after FDA leadership shakeup Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026